

PLEASE NOTE: Legislative Information **cannot** perform research, provide legal advice, or interpret Maine law. For legal assistance, please contact a qualified attorney.

**An Act To Provide the Office of Chief Medical Examiner Access
to Controlled Substances Prescription Monitoring Program Data
for the Purpose of Conducting Cause of Death Investigations**

Be it enacted by the People of the State of Maine as follows:

Sec. 1. 22 MRSA §7250, sub-§4, ¶D, as enacted by PL 2003, c. 483, §1, is amended to read:

D. A patient to whom a prescription is written, insofar as the information relates to that patient; ~~and~~

Sec. 2. 22 MRSA §7250, sub-§4, ¶E, as enacted by PL 2003, c. 483, §1, is amended to read:

E. Office personnel or personnel of any vendor or contractor, as necessary for establishing and maintaining the program's electronic system-; and

Sec. 3. 22 MRSA §7250, sub-§4, ¶F is enacted to read:

F. The Office of Chief Medical Examiner for the purpose of conducting an investigation or inquiry into the cause, manner and circumstances of death in a medical examiner case as described in section 3025. Prescription monitoring information in the possession or under the control of the Office of Chief Medical Examiner is confidential and, notwithstanding section 3022, may not be disseminated.

SUMMARY

This bill amends the controlled substances prescription monitoring laws to authorize Office of Chief Medical Examiner access to prescription monitoring information. Office of Chief Medical Examiner access would be for the limited purpose of conducting investigations into the cause, manner and circumstances of death in medical examiner cases. The bill specifies that prescription monitoring information under the possession or control of the Office of Chief Medical Examiner is confidential and may not be further disseminated.